Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA has approved Gilead Sciences’ hotly anticipated new hepatitis C therapy Harvoni (ledipasvir/sofosbuvir).
By year’s end, a new crop of interferon-free hepatitis C combination therapies will likely hit the market.
I am outraged that Gilead refuses to study 7977 with other DAAs that are farther along than their own drugs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.